ORAGENICS INC — Director's Dealing 2017

Nov 13, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAGENICS INC (OGEN)
CIK: 0001174940
Period of Report: 2017-11-08

Reporting Person: KOSKI FAMILY LP (10% Owner)
Reporting Person: KOSKI ROBERT C (Director, 10% Owner)
Reporting Person: KOSKI THOMAS L (10% Owner)
Reporting Person: KOSKI CHRISTINE L (10% Owner)
Reporting Person: KOSKI BEVERLY (10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-11-08	Series B Convertible Preferred Stock	$0.25	J	1500000	Acquired		Common Stock (3000000)	Direct
2017-11-08	Common Stock Warrant	$0.31	J	2419355	Acquired	2024-11-08	Common Stock (2419355)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	12864822	Direct
Common Stock	1572523	Direct
Common Stock	1087878	Direct
Common Stock	519666	Direct
Common Stock	20000	Indirect
Common Stock	530851	Indirect

Footnotes

F1: Shares owned directly by Koski Family Limited Partnership ("KFLP"). Shares owned indirectly by the KFLP general partners: Koski Management, Inc. (solely owned by Beverly Koski), Christine L. Koski, Robert C. Koski and Thomas L. Koski, each of whom is a general partner of the partnership or the controlling person of a corporate general partner of the partnership.

F2: Each reporting person disclaims beneficial ownership of all indirectly owned securities in excess of such reporting person's pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner for purposes of Section 16 or any other purpose.

F3: Shares owned directly by Christine L. Koski.

F4: Shares owned directly by Robert C. Koski, a director of the Company.

F5: Shares owned directly by Thomas L. Koski.

F6: Shares owned indirectly by Beverly Koski (through Koski Management, Inc.).

F7: Shares owned by trusts of which Mr. Robert C. Koski is sole trustee. Such trusts are as follows: the Robert Clayton Koski Trust for the benefit of Anthony James Hunter (100,000 shares); the Robert Clayton Koski Trust for the benefit of Hunter Buchanan Koski (100,000 shares); the Robert Clayton Koski Trust for the benefit of Clayton Ward Bennett (100,000 shares); the Robert Clayton Koski Trust for the benefit of Robert Edward Koski (100,000 shares); and the Robert Clayton Koski Trust for the benefit of Elyse Margaux Koski (97,666 shares). Mr. Koski disclaims beneficial ownership of the shares held by the trusts except to the extent of any pecuniary interest.

F8: On November 8, 2017 the Company issued to the KFLP 1,500,000 shares of Series B Preferred Stock at a purchase price of $0.50 per share which are convertible into 3,000,000 shares of the Company's Common Stock, based on a conversion ratio of one share of Series B Preferred Stock into two shares of common stock. The purchase price per share represented by the shares of common stock the Series B Preferred Stock is convertible into equates to $0.25 per share. The Series B Convertible Preferred Stock will be convertible into shares of common stock commencing on the effective date of shareholder approval and has no expiration date.

F9: On November 8, 2017, the Company issued to the KFLP in the private placement a warrant to purchase 2,419,355 shares of Common Stock. The Warrant has a term of seven years from the date of issuance, are non-exercisable until 6 months after issuance, and have an exercise price of $0.31 per share. The exercisability of the Warrant into shares of common stock is also subject to shareholder approval.